Building from our clinical discovery that stroke patients suffer from tPA-induced HT featured strong expression of CD177, recombinant CD177 protein (rCD177) was loaded into CP polymersomes (CP@rCD177) as nanomedicine and administrated prior to CP@tPA thrombolysis. This evidence concerns the gene CD177 and hematocrit.